Allotment of scrip shares and total voting rights

For immediate release                                                                                    

3 January 2018

MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")

Allotment of scrip shares to Directors

and Investment Adviser and total voting rights

Members of the Company's Board of Directors elected to participate in the Company's scrip dividend scheme in respect of the December 2017 dividend for the quarter ended 30 September 2017, and accordingly acquired ordinary shares of no par value in the Company (the "Shares") as disclosed in the table below.

The Shares were acquired on 29 December 2017 and rank pari passu with the Company's existing ordinary shares.

The Directors detailed above, who elected to participate in the Company's scrip dividend scheme, did so under an election mandate which remains in place until revoked. 

Octopus Healthcare Adviser Ltd (the Company's Investment Adviser) also elected to participate in the Company's scrip dividend scheme in respect of the December 2017 dividend for the quarter ended 30 September 2017, and accordingly was allotted 40,684 ordinary shares of no par value in the Company (the "Shares").  The Shares were sold out of treasury at the previously advised scrip calculation price of 84.7 pence per share.

The acquisition of the Shares brings Octopus Healthcare Adviser Ltd's total holding in the Company to 2,338,020 shares, representing 0.55% of the Company's total voting rights.  The Shares were acquired on 29 December 2017 and rank pari passu with the Company's existing ordinary shares.

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the total number of ordinary shares of the Company in issue as at 29 December 2017 was 428,833,331 (excluding treasury shares) with each share holding one voting right.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure and Transparency Rules.

The Company also holds 7,169,068 ordinary shares in treasury and has 14,771,668 ordinary shares of no par value remaining under its block listing facility.

Copies of the documents relating to the Scrip Dividend Alternative are available for inspection through the National Storage Mechanism (http://www.morningstar.co.uk/uk/NSM).

End

For further information please contact:

MedicX Fund                                                                  +44 (0) 1481 723 450

David Staples, Chairman

Octopus Healthcare Group                                               +44 (0) 20 3142 4820

Mike Adams, Chief Executive Officer

Buchanan                                                                      +44 (0) 20 7466 5000

Charles Ryland/Vicky Hayns

Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", "the Fund" or "the Company", or together with its subsidiaries, "the Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 153 properties.

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over £1.2 billion of healthcare investments across a number of platforms, with a focus on five core areas: GP surgeries, care homes, special education schools, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages £7 billion of funds for more than 50,000 retail and institutional investors as well as supplying energy to more than 100,000 customers

Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.

The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.

The Company's Legal Entity Identifier is 2138008POF35FTNFCB25